US2770569A - Analgesic compositions - Google Patents

Analgesic compositions Download PDF

Info

Publication number
US2770569A
US2770569A US314954A US31495452A US2770569A US 2770569 A US2770569 A US 2770569A US 314954 A US314954 A US 314954A US 31495452 A US31495452 A US 31495452A US 2770569 A US2770569 A US 2770569A
Authority
US
United States
Prior art keywords
hydroxy
levo
morphinan
allyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US314954A
Inventor
Fromherz Konrad
Gruessner Andre
Pellmont Bela
Schnider Otto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann-La Roche AG
Hoffmann-La Roche Inc
Original Assignee
F Hoffmann-La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CH2770569X priority Critical
Application filed by F Hoffmann-La Roche AG filed Critical F Hoffmann-La Roche AG
Application granted granted Critical
Publication of US2770569A publication Critical patent/US2770569A/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine

Description

Patented Nov. 135,

ANALGESHI (IOMPOSITIONS Konrad Fromlierz, Andre Grnessner, Bela Pellmont, and

Otto Schnider, Basel, Switzerland, assignors to Hoffmann-La Roche Inc, Nutley, N. 3., a corporation of New Jersey No Drawing. Application Uctobcr 15, 1952, Serial No. 314,954

Claims priority, application Switzerland August 1, 1952 6 Claims. (Cl. 167--65) This invention relates to compositions of matter useful in therapy to produce analgesia. It relates especially to such compositions wherein undesired side effects common to analgesics, particularly respiratory depression, are diminished or suppressed by incorporation of material which antagonizes the tendency of the analgesic material to produce such side effects.

Morphine-type analgesics have found extensive medical application because of their fi"1cacy even in cases of very severe pain. However, overdoses of such analgesics often are attended by very serious side reactions. In addition, many people react even to minimal therapeutic doses by exhibiting similar side reactions, which are mainly evidenced in the form of respiratory depression, nausea, and vomiting. In the management of labor, analgesic medication administered to the mother often results in respiratory depression of the newborn infant.

The present invention rests upon the discovery that levo-3-hydroxy-N-allyl-rnorphinan, either in the form of the free base or in the form of its acid addition salts, has the characteristic of suppressing or eliminating undesired side reactions of morphine-type analgesics. Surprisingly, it has been found that this antagonistic effect of 3-hydroxy-N-allyl-morphinan is limited to the levo enantiomorph thereof; the dextro form having little or no antagonistic effect; and the racemic form having the activity only of its levo content.

The antagonistic effect of levo-3-hydroxy-N-allylmorphinan extends not only to the undesired side reactions of morphine-type analgesics but also extends to the analgesic activity itself. Accordingly, the dosage of the antagonist, levo-3-hydroxy-N-allylmorphinan, must be carefully proportioned with respect to the dosage of the analgesic material so as to diminish or suppress the side reactions without significantly influencing the desired analgesic action. Fortunately, the effect of a small proportion of levo-3-hydroxy-N-allyl-morphinan upon the side reactions, particularly the respiratory depressive effect, is considerable; whereas the antagonistic effect on the analgesic action, produced by that same small proportion of levo-3-hydroxy-N-allyl-morphinan, is small. It has been found that good results have been obtained when the proportion of levo-3-hydroxy-N-allyl-morphinan is from about to about by weight of the morphinetype analgesic material. It will be appreciated by those skilled in the art, however, that these numerical values are not absolutely limiting; and compositions wherein the proportion of analgesic material and antagonist material differs slightly from the range indicated above, but which exhibit the desirable qualities indicated in this disclosure, are equivalent to the compositions described in detail herein and are comprehended within the scope of the invention disclosed in this specification.

Accordingly, the present invention provides compositions of matter containing as essential therapeutic ingredients morphine-type analgesic material and antagonist maicrial selected from the group consisting of levo-3-hydroxy-N-allyl-morphinan and its acid addition salts, the effective content of levo-3-hydroxy-N-allyl-morphinan in said compositions being from about 0.5 percent to about 10 percent by weight of said analgesic material.

Morphine-type analgesics includes morphine itself and analgesically active derivatives and synthetic substitutes therefor, as discussed in parts II and III of a paper by Bergel and Morrison in Quarterly Reviews of the Chemical Society, vol. II, pages 349-382 (194-8), and in a paper by Eddy in Journal of the American Pharmaceutical Association (Scientific Edition) vol. 39, pages 245251 (1950). Illustrative morphine-type analgesics include morphine and its derivatives, 3-hydroxy-N-methyl-morphinan, 1-methyl-4-phenyl-piperidine-4carboxylic acid ethyl ester, 1,3-dimethyl-4-phenyl-4-propionoxypiperidine, 1-methyl-4- (m-hydroxyphenyl) -piperidine-4- ethyl ketone, 4,4-diphenyl-6-dimethylamino-heptan-3-one and acid addition salts thereof. It will be understood by those skilled in the art that these analgesic materials can be used either as the free bases or in the form of their acid addition salts, and can be used individually or in combination with each other when desirable. Moreover, since these compounds typically exhibit optical isomerism, it will be understood that any of the optically active or racemic forms possessing significant analgesic activity can be used in practicing the invention. Mixtures of free bases and salts, or of racemic and optically active forms, or of analgesics having different chemical constitutional formuias, or any combination of tl foregoing materials, can be employed.

Similarly, since racemic 3-hydroxy-Nallyl-1norphinan exhibits the antagonistic effect discussed. above, in consequence of its content of the levo enantiomorph, it should be understood that the levo content of the compositions of the invention may be present in whole or in part as a constituent of racemic 3-hydroxy-N-allyl-rnorphinan. Likewise, the antagonist may be used either in the form of the free base 3-hydroxy-N-allyl-morphinan, or in the form of an acid addition salt of 3-hydroxy-N allyl-mon phinan, or as a mixture of the base and acid addition salts thereof, either levo or racemic.

The total content of antagonist material present in compositions of matter according to the invention should provide from about 0.5 percent by weight to about 10 percent by Weight of the free base levo-3-hydroxy-N allyl'morphinan, based upon the total weight of analgesic material in the composition. In addition to their analgesic content and antagonist content, it will be obvious to those skilled in the art that compositions of matter according to the invention may also be formulated to contain pharmaceutical adjuvant material of various sorts, e. g. carriers, buffers, antiseptics, flavoring agents, stabilizers, diluents and the like.

A preferred aspect of the invention relates to compositions of matter containing as essential therapeutic ingredients: analgesic material selected from the group consisting of morphine, dihydrodesoxymorphine, 3-hydroxy- N--methyl-morphinan, 1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester, l,3-dimethyl-4-phenyl-4-propionoxy-riperidine, 1-methyl-4-(m-hydroxyphenyl -piperidinetethyl ketone, 4,4-diphenyl-6-dimethylaminoheptan-3- one and acid addition salts thereof; and antagonist maerial selected from the group consisting of levo-3-hydroxyl-sllyl-morphinan and its acid addition salts; the effective cor out of levo-3-hydroxy-N-ally1-morphinan in said composit. .n being from about 0.5 percent to about 19 percent by weight of said analgesic material.

A particularly preferred embodiment of the invention relates to compositions of matter in dosage unit form consisting essentially of an acid addition salt of levo-3- hydroxy-Nanethyl-morphinan, an acid addition salt of 3 lave-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy- N-allyl-morphinan to said levo-3-hydroxy-N-methylmorphinan being from about 0.5 percent to about 10 percent by weight.

A second particularly preferred embodiment of the in vention relates to compositions of matter in dosage unit form consisting essentially of an acid addition salt of racemic-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-rnorphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy-N-allyhmorphinan to said racemic-3-hydroxy-N- methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

The invention is further disclosed in the following examples, which are illustrative but not limitative thereof.

Example 1 To a paste prepared from 54 g. of cornstarch, were added 1.5 g. of levo-3-hydroxy-N-methyl-morphinan tartrate, 0.1 g. of levo-3-hydroxy-N-allyl-morphinan tartrate, 90 g. of milk sugar, 4.2 g. of talc, and 0.2 g. stearin. The ingredients were mixed homogeneously, the whole granulated through a sieve, dried, and made up into tablets, each weighing 150 mg. and each containing 1.5 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate and 0.1 mg. levo-3-hydroxy-N-allyl-morphinan tartrate.

Another type of tablets was made, exactly similar to those described above, except that the 1.5 mg. of levo- 3-hydroxy-N-methyl-morphinan tartrate was replaced by 3.0 mg. of racemic-3-hydroxy-N-methyl-morphinan tartrate.

Tablets similar to those described above were made by substituting 20 mg. of morphine hydrochloride for the 1.5 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate.

Tablets similar to those described above were also made by substituting mg. of 1-methyl-4-(m-hydroxyphenyl)- piperidine-4-ethyl-ketone hydrochloride for the 1.5 mg. of levo-3hydroxy-N-methyl-morphinan tartrate.

Example 2 3 g. of dihydrodesoxymorphine hydrobromide, and 0.1 g. of levo-3-hydroxy-IJ-allyl-rnorphinan hydrobromide were dissolved in a mixture of cc. of water and 30 cc. of ethanol, and mixed with 2000 g. of cocoa butter and 100 g. of white wax to form a homogeneous mass. From the latter were prepared suppositories each containing 3 mg. of dihydrodesoxymorphine hydrobromide and 0.1 mg. of levo-3-hydroXy-N-allyl-morphinan hydrobromide.

Example 3 A solution was prepared from double distilled water containing in each cc. 4 mg. of dihydrodesoxymorphine hydrobromide, and 0.1 mg. of levo-3-hydroxy-N-allylmorphinan hydrobromide. The solution was filled into ampuls and heated for minutes at 95 C. in order to sterilize the same.

Example 4 In 900 cc. of double distilled water were dissolved 0.8 g. of p-hydroxy-benzoic acid methyl ester 0.1 g. of p-hydroxy-benzoic acid propyl ester 3.0 g. of levo-3-hydroxy-N-methyl-morphinan tartrate 0.15 g. of levo-3-hydroxy-N-allyl-morphinan tartrate.

The solution was set to pH 6.0 by adding approximately 7.4 cc. of normal NaOH, adjusted to 1000 cc. with double distilled water and filled into 1 cc. ampuls.

Example5 9 g. of levo-3-hydroxy-N-methyl-morphinan tartrate,

and 0.45 g. of lev0-3 hydroxy-N-allyl-morphinan tartrate were dissolved in 165 cc. of ethanol, 2.4 g. of p-hydroxy benzoic acid methyl ester and 0.3 g. of p-hydroxy benzoic acid propyl ester were added, the clear solution was set to 3000 cc. with double distilled water, and filtered. This solution can be prescribed for administration as a drops solution. Twenty drops, corresponding to about 1 cc., contain 3 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate and 0.15 mg. of 3-hydroxy-N-allyl-morphinan tartrate.

We claim:

1. A composition of matter in a form for administration by injection containing as essential therapeutic ingredients: analgesic material selected from the class consisting of morphine, dihydrodesoxymorphine, 3-hydroxy-N-methylmorphinan, 1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester, l,3dimethyl-4-phenyl-4-propionoxy-piperidine, l-methyl-4-(m-hydroxyphenyl) piperidine4-ethyl ketone, 4,4-diphenyl-6-dimethylamino-heptan-3-one and acid addition salts thereof; and antagonist material selected from the group consisting of levo-3-hydroxy-N-allylmorphinan and its acid addition salts; the effective content of levo-3-hydroxy-N-allyl-morphinan in said composition being from about 0.5 percent to about 10 percent by Weight of said analgesic material.

2. A composition of matter in dosage unit form for administration by in ection consisting essentially of an acid addition salt of 1evo-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo3-hydroxy-N-allyl-morphinan to said levo-3-hydroxy-N-methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

3. A composition of matter in dosage unit form for administration by injection consisting essentially of an acid addition salt of racemic-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy-N-allyl-morphinan to said racemic-3 hydroxy-N-methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

4. A composition of matter in a form for administration by injection containing as essential therapeutic ingredients morphine-type analgesic material and antagonist material selected from the group consisting of levo-3-hydroxy-N-allyl-rnorphinan and its acid addition salts, the effective content of levo-3-hydroxy-N-allyl-morphinan in said composition being from about 0.5 percent to about 10 percent by weight of said analgesic material.

5. A composition according to claim 4 wherein said morphine-type analgesic material comprises a substantial 1 proportion of levo-3-hydroxy-N-methyl-morphinan.

6. A composition according to claim 4 wherein said morphine-type analgesic material comprises a substantial proportion of an acid addition salt of levo-3-hydroxy-N- methyl-morphinan.

Claims (1)

  1. 4. A COMPOSITION OF MATTER IN A FORM FOR ADMINISTRATION BY INJECTION CONTAINING AS ESSENTIAL THERAPEUTIC INGREDIENTS MORPHINE-TYPE ANALGESIC MATERIAL AND ANTAGONIST MATERIAL SELECTED FROM THE GROUP CONSISTING OF LEVO-3-HYDROXY-N-ALLYL-MORPHINAN AND ITS ACID ADDITION SALTS, THE EFFECTIVE CONTENT OF LEVE-3-HYDROXY-N-ALLYL-MORHPINAN IN SAID COMPOSITION BEING FROM ABOUT 0.5 PERCENT TO ABOUT 10 PERCENT BY WEIGHT OF SAID ANALGESIC MATERIAL.
US314954A 1952-08-01 1952-10-15 Analgesic compositions Expired - Lifetime US2770569A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH2770569X 1952-08-01

Publications (1)

Publication Number Publication Date
US2770569A true US2770569A (en) 1956-11-13

Family

ID=4571651

Family Applications (1)

Application Number Title Priority Date Filing Date
US314954A Expired - Lifetime US2770569A (en) 1952-08-01 1952-10-15 Analgesic compositions

Country Status (1)

Country Link
US (1) US2770569A (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3285922A (en) * 1962-01-26 1966-11-15 Research Corp N-cyclopropylmethyl-and -cyclobutyl-methyl-morphinans
US3301855A (en) * 1963-04-22 1967-01-31 Ciba Geigy Corp Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
US3320262A (en) * 1964-09-22 1967-05-16 Lewenstein 14 hydroxy morphine and codeine carboxymethyloximes
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6696088B2 (en) 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
USRE39221E1 (en) 1991-09-06 2006-08-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and acetaminophen and its use
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US20060280801A1 (en) * 2004-09-16 2006-12-14 Kronenthal Richard L Compositions and method for the reduction of post-operative pain
US7384653B2 (en) 2001-08-06 2008-06-10 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683106A (en) * 1949-07-28 1954-07-06 Lewenstein Mozes Juda Analgesic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683106A (en) * 1949-07-28 1954-07-06 Lewenstein Mozes Juda Analgesic composition

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3285922A (en) * 1962-01-26 1966-11-15 Research Corp N-cyclopropylmethyl-and -cyclobutyl-methyl-morphinans
US3301855A (en) * 1963-04-22 1967-01-31 Ciba Geigy Corp Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
US3320262A (en) * 1964-09-22 1967-05-16 Lewenstein 14 hydroxy morphine and codeine carboxymethyloximes
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
USRE39221E1 (en) 1991-09-06 2006-08-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US6475494B2 (en) 1997-12-22 2002-11-05 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US6696066B2 (en) 1997-12-22 2004-02-24 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6627635B2 (en) 1997-12-22 2003-09-30 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US7172767B2 (en) 1997-12-22 2007-02-06 Purdue Pharma L.P. Opioid agonist / antagonist combinations
US8105631B2 (en) 1997-12-22 2012-01-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US7419686B2 (en) 1997-12-22 2008-09-02 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8936808B1 (en) 1997-12-22 2015-01-20 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US7749542B2 (en) 1997-12-22 2010-07-06 Purdue Pharma Lp Opioid agonist/antagonist combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US9474750B2 (en) 1997-12-22 2016-10-25 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US7718192B2 (en) 2000-02-08 2010-05-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7682632B2 (en) 2000-02-08 2010-03-23 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842309B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842311B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9801828B2 (en) 2000-02-08 2017-10-31 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6696088B2 (en) 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US8236351B2 (en) 2000-02-08 2012-08-07 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8586088B2 (en) 2000-02-08 2013-11-19 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8357399B2 (en) 2000-02-08 2013-01-22 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9084729B2 (en) 2001-05-11 2015-07-21 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9056051B2 (en) 2001-05-11 2015-06-16 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US8231901B2 (en) 2001-08-06 2012-07-31 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
USRE45822E1 (en) 2001-08-06 2015-12-22 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9949930B2 (en) 2001-08-06 2018-04-24 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8758825B2 (en) 2001-08-06 2014-06-24 Purdue Pharma L.P. Sequestered antagonist formulations
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7384653B2 (en) 2001-08-06 2008-06-10 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US8518443B2 (en) 2001-08-06 2013-08-27 Purdue Pharma, L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8815287B2 (en) 2001-08-06 2014-08-26 Purdue Pharma L.P. Opiod agonist formulations with releasable and sequestered antagonist
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8703186B2 (en) 2003-04-08 2014-04-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8425933B2 (en) 2003-04-08 2013-04-23 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US10092519B2 (en) 2003-04-21 2018-10-09 Purdue Pharma L.P. Pharmaceutical products
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US20060280801A1 (en) * 2004-09-16 2006-12-14 Kronenthal Richard L Compositions and method for the reduction of post-operative pain
US8603528B2 (en) * 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Similar Documents

Publication Publication Date Title
US3652589A (en) 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3174901A (en) Process for the oral treatment of diabetes
Stein Anticholinergic drugs and the central control of thirst
Nestel et al. The effect of chlorophenoxyisobutyric acid and ethinyl estradiol on cholesterol turnover
US5112838A (en) Method of treating psychoses in human beings with the atypical neuroleptic 5-chloro-1-(4-fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl-4-piperidyl)1h-indole
DE2749950C2 (en)
Patil et al. A pharmacological study of the ephedrine isomers
US3799934A (en) Unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
US4663318A (en) Method of treating Alzheimer's disease
Benson et al. Comparative pharmacology of levorphan, racemorphan and dextrorphan and related methyl ethers
DE3152519C2 (en) New fenofibrate Fertigpr {ready with verz|gerter release
US6348456B1 (en) Method of treating chemical dependency in mammals and a composition therefor
DE4035442B4 (en) A medicament comprising as an active substance R-α-lipoic acid
ES2120451T7 (en) Composition comprising a compound of tramadol and acetaminophen, and its use.
Davidson et al. Studies with the serotonin precursor, 5-hydroxytryptophan, in experimental animals and man
Davis Effects of central excitant and depressant drugs on locomotor activity in the monkey
EP0299602B1 (en) Use of indolone derivatives for the preparation of medicaments for the treatment of parkinsons disease
Papke et al. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes
Loveless et al. A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor
DE60116352T2 (en) Use of KCNQ potassium channel agonists for preparing a medicament for the modulation of bladder function
Long et al. A new series of cholinesterase inhibitors
Lambertsen et al. The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2
AU614710B2 (en) Stabilized drug compositions
US4939175A (en) Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs